Fast, high-throughput production of improved rabies viral vectors for specific, efficient and versatile transsynaptic retrograde labeling

  1. Anton Sumser
  2. Maximilian Joesch
  3. Peter Jonas
  4. Yoav Ben-Simon  Is a corresponding author
  1. Institute of Science and Technology Austria (ISTA), Austria
  2. Department of Neurophysiology and Neuropharmacology, Vienna Medical University, Austria
  3. Allen Institute for Brain Science, United States

Decision letter

  1. Rebecca Seal
    Reviewing Editor; University of Pittsburgh School of Medicine, United States
  2. Laura L Colgin
    Senior Editor; University of Texas at Austin, United States
  3. Ian Wickersham
    Reviewer; Massachusetts Institute of Technology, United States

Our editorial process produces two outputs: (i) public reviews designed to be posted alongside the preprint for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.

Decision letter after peer review:

Thank you for submitting your article "Fast, high-throughput production of improved rabies viral vectors for specific, efficient and versatile transsynaptic retrograde labeling" for consideration by eLife. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by Rebecca Seal as the Reviewing Editor and Laura Colgin as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Ian Wickersham (Reviewer #2).

The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.

Essential revisions:

1) The authors claim that the titer efficiency is high but do not clearly show the titers which should be calculated for virus harvested from cells expressing TVA and from cells not expressing TVA.

2) The authors claim that there is no contamination with G-coated rabies but do not show it. The authors need to demonstrate the level of background contamination by injecting the rabies without the TVA in WT mice. Leak expression from Cre-dependent "starter" AAVs should also be tested by injecting them and rabies in WT mice.

3) To improve the clarity of the manuscript, the authors should address all other points outlined by the reviewers below, which will not require any new experiments.

Reviewer #1 (Recommendations for the authors):

The authors should examine the time course of health of the retrogradely infected cells and starter cells with electrophysiological measurements of membrane potential or a histological stain.

Extended Data Figure 7 seems errantly labeled in C. Number of neurons?

Abbreviations in figures should be defined in figure legends.

https://doi.org/10.7554/eLife.79848.sa1

Author response

Reviewer #1 (Recommendations for the authors):

The authors should examine the time course of health of the retrogradely infected cells and starter cells with electrophysiological measurements of membrane potential or a histological stain.

We thank the reviewer for this suggestion. We have added resting potential information of retrogradely infected cells and starter cells at ~ 7 days post injection (Figure 6D).

Regarding the time course of neuronal health beyond this point, the situation is more complex. Reardon et al., 2016 reported anecdotal evidence that channelrhodopsin stimulation was possible until 28 days after infection. However, other assays of integrity in this paper showed signs of degeneration at much earlier stages (e.g. increase of propidium iodide-positive cells 4 days after infection). Although we have obtained patch recordings at later times after injection, we had the impression that the – number – of labeled cells decreased, and that it is more difficult to get recordings. However, this is difficult to quantify, because of the high variability of labelling across animals. Furthermore, it is well known that neurons become less healthy and more difficult to record by electrophysiology in older animals, even in wild-type. Thus, after careful consideration, we arrived at the conclusion that obtaining compelling data will be difficult.

We also want to emphasize that the rabies virus-mediated expression of both ChIEF and GCaMP8 is highly powerful and has a fast onset. Therefore, we are sure that both actuator and/or indicator expression reach sufficiently high levels after ~5 days. Thus, although the health of neurons may decline at later times after infection, there is a large window in which meaningful functional connectivity measurements can be obtained. We have now mentioned this in the Results / Discussion section of the revised version (p. 11, top of the revised manuscript).

We hope that the reviewer can accept our reply, which represents an honest answer to a tricky question.

Extended Data Figure 7 seems errantly labeled in C. Number of neurons?

ED Figure 7c (now Figure 7 —figure supplement 9C) indeed shows the development of fluorescence SNR over time. To avoid confusion, the text describing the results has been revised to enable easier interpretation.

Abbreviations in figures should be defined in figure legends.

We have carefully reviewed all figure legends and made sure that all abbreviations are properly defined.

https://doi.org/10.7554/eLife.79848.sa2

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Anton Sumser
  2. Maximilian Joesch
  3. Peter Jonas
  4. Yoav Ben-Simon
(2022)
Fast, high-throughput production of improved rabies viral vectors for specific, efficient and versatile transsynaptic retrograde labeling
eLife 11:e79848.
https://doi.org/10.7554/eLife.79848

Share this article

https://doi.org/10.7554/eLife.79848